Invenomic Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Applovin
APP
|
+$58.8M |
| 2 |
Lyft
LYFT
|
+$27.4M |
| 3 |
Clarivate
CLVT
|
+$26.3M |
| 4 |
Frontdoor
FTDR
|
+$24.5M |
| 5 |
Salesforce
CRM
|
+$23.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$27.1M |
| 2 |
Universal Health Services
UHS
|
+$22.3M |
| 3 |
POSH
Poshmark, Inc. Class A Common Stock
POSH
|
+$21M |
| 4 |
Cabot Corp
CBT
|
+$18.2M |
| 5 |
CIVI
Civitas Resources
CIVI
|
+$17.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.82% |
| 2 | Consumer Discretionary | 14.98% |
| 3 | Communication Services | 13.53% |
| 4 | Healthcare | 8.23% |
| 5 | Industrials | 8.05% |
Similar funds
Invenomic Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Invenomic Capital Management held 179 positions worth $1.47B, up 27% from $1.16B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Invenomic Capital Management deployed $259M of net new capital in Q4 2022, opening 33 new positions and adding to 51 existing holdings. Its largest new stake was Clarivate: 2,805,166 shares worth $23.4M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Consumer Discretionary and Communication Services.
On the sell side, the largest reduction was Universal Health Services, an estimated $22.3M trimmed.
- Invenomic Capital Management's largest Q4 2022 buy was Clarivate: 2,805,166 shares worth $23.4M.
- Invenomic Capital Management added most to Applovin in Q4 2022, an estimated $58.8M increase.
- Invenomic Capital Management's biggest Q4 2022 reduction was Universal Health Services, cutting an estimated $22.3M.
- Invenomic Capital Management fully exited Cisco in Q4 2022, selling an estimated $27.1M.
- Invenomic Capital Management's ten largest holdings make up 27% of its $1.47B portfolio in Q4 2022.
- Invenomic Capital Management opened 33 new positions and closed 39 in Q4 2022.
- Invenomic Capital Management's portfolio value rose 27% quarter-over-quarter to $1.47B.
Based on Invenomic Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.